Last edition
News about Clinical Trials
Life Biosciences Doses First Patient in Phase 1 ER-100 Optic Neuropathy Trial
Life Biosciences has dosed the first patient in its phase 1 trial of ER-100, an investigational epigenetic restoration therapy for glaucoma and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The study marks a key milestone in evaluating a novel approach that targets the underlying causes of age-related vision loss.
Clinical Trials | 09/06/2026 | By News Bureau
Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill
Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.
Clinical Trials | 09/06/2026 | By News Bureau
Coya Therapeutics Advances ALSTARS Trial into Active-Treatment Extension Phase
Coya Therapeutics announced that the first cohort of ALS patients in the ALSTARS trial has entered the 24-week blinded active-treatment extension phase, where all participants will receive COYA 302.
Clinical Trials | 09/06/2026 | By News Bureau
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
Clinical Trials | 08/06/2026 | By News Bureau
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
Clinical Trials | 08/06/2026 | By News Bureau
Omnix Medical has initiated patient dosing in its Phase 2 clinical trial of OMN6, a novel antimicrobial peptide designed to treat severe multidrug-resistant Acinetobacter baumannii infections, a critical global health threat with limited treatment options.
Clinical Trials | 05/06/2026 | By News Bureau
Johnson & Johnson's Nipocalimab Shows Sustained Disease Reduction in Lupus Phase 2 Study
The monoclonal antibody met its primary endpoint in the JASMINE trial and demonstrated continued improvements in disease activity through 52 weeks in adults with moderate-to-severe systemic lupus erythematosus.
Clinical Trials | 04/06/2026 | By News Bureau
Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial
Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Clinical Trials | 03/06/2026 | By News Bureau
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.
Clinical Trials | 01/06/2026 | By News Bureau
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
Clinical Trials | 01/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy